+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Modulation of experimental systemic murine candidosis by intravenous pepstatin

Modulation of experimental systemic murine candidosis by intravenous pepstatin

Zentralblatt fuer Bakteriologie 273(3): 391-403

The effect of intravenous pepstatin-A on systemic candidosis in NWNI mice was investigated. True solutions of the inhibitor proved ineffective due to a very fast clearance. Pepstatin was effective as a crystal suspension (0.69 mg in 0.1 ml saline) which produced serum inhibitory activity for > 29 h. From the intravenously applied suspension, pepstatin was taken up predominantly into the liver, no inhibitor being taken up by the kidneys. The suspension was protective if it was injected once before the mice were infected and repeatedly following infection. It was also effective if it was administered concomitantly with the infecting agent and thereafter. The suspension was ineffective if it was only given once before infection, and it proved to be detrimental if it was given only after infection. The results support previous findings (2), suggesting a role of fungal proteinase early in the adherence of Candida to host epithelia. Our results also suggest an inhibition of lysosomal cathepsin-D in vivo by pepstatin, which prohits a parenteral therapeutic use of non-modified pepstatin A.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 007560145

Download citation: RISBibTeXText

PMID: 2206206

DOI: 10.1016/s0934-8840(11)80443-3

Related references

Evaluation of himachalol in murine systemic candidosis. Journal de Mycologie Medicale 9(4): 217-220, 1999

Efficacy of the partricin derivative SPA-S-753 against systemic murine candidosis. Journal of Antimicrobial ChemoTherapy 47(2): 183-186, 2001

Efficacy of the partricin derivative, IB-643, against systemic murine candidosis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 469, 1998

Intravenous immunoglobulins prevents experimental fibrosis in a murine model of systemic sclerosis. La Revue de Médecine Interne 38: A50-A51, 2017

Differential effects of CD4+ and CD8+ cells in acute, systemic murine candidosis. Journal of Leukocyte Biology 51(3): 305-306, 1992

Comparison of oral imidazoles in therapy of systemic candidosis in a murine model. Abstracts Of The Annual Meeting Of The American Society For Microbiology: Stract F1, 1984

Experimental oral murine candidosis and attempts of prevention. Journal de Mycologie Medicale 9(1): 10-15, 1999

Chemotherapy of chronic mucocutaneous candidosis and systemic candidosis treated by oral ketoconazole. Chemotherapie von Oberflachen , Organ und Systemmykosen I Deutsches Nizoral Symposium: 58-68, 1982

Histopathology of experimental systemic candidosis in guinea-pigs. Sabouraudia 22(6): 455-469, 1984

Kidney function in experimental systemic candidosis of mice. Mycoses 31(4): 203-207, 1988

Migratory activity of granulocytes over the course of experimental systemic candidosis. Vestnik Dermatologii i Venerologii (6): 22-25, 1988

Dispersion of germ tubes of Candida albicans in serum of experimental murine candidosis. Yeasts and yeast like microorganisms in medical science Proceedings of the Second International Specialized Symposium on Yeasts Tokyo 1972: 157-159, 1976

An experimental model for murine vaginal candidosis application to the screening of potential antifungal drugs. Revista Iberoamericana de Micologia 9(2): 35-37, 1992

Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naive mice. Journal of Antimicrobial ChemoTherapy 44(6): 787-790, 1999

Experimental systemic candidosis influence of antifungal treatment and of immunosuppression with cyclophosphamide on humoral response to the mycelial phase of candida albicans. Revista Iberica de Micologia 5(1): 30-40, 1988